Condition: Sepsis · Trauma Injury · Sponsor: University of Florida
Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.
This description comes directly from the study's public registry record.
Jennifer Lanz, MSN · 352-273-5497 · jennifer.lanz@surgery.ufl.edu
Ruth Davis, BSN · 352-273-5897 · ruth.davis@surgery.ufl.edu
Always discuss trial participation with your own doctor first.
| UF Health at Shands hospital | Gainesville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05110937